FDA Opens Year Five of the CMC Development and Readiness Pilot: What a Credible CMC Development Plan Has to Show
What FDA asks sponsors to include in a CMC development plan, and how to keep its statements aligned through filing
Why Your CMC Structured Authoring Initiative Is Stalling: The Statement-Level Governance Gap That Structure Alone Cannot Close
CMC structured authoring improves reuse. Statement-level governance controls change A CMC regulatory affairs director, eighteen months into a modularization initiative,
What ICH M4Q(R2) Demands From Your CMC Content Architecture
ICH M4Q(R2) restructures how CMC content is organized within the CTD. This article explains what the revision means for structured authoring, PQ/CMC readiness, and global submission planning.
PQ-CMC and the Leadership Imperative: Why CMC Content Governance Is Now a Board-Level Risk Decision
Pharmaceutical Quality–Chemistry, Manufacturing, and Controls (PQ-CMC) is often framed as a technical modernization effort—a move toward structured data, improved submission
From Module 3 to Managed Risk: Why CMC Content Architecture Determines Regulatory Control
For Chemistry, Manufacturing, and Controls (CMC) and regulatory leaders, confidence in regulatory outcomes depends less on the quality of any
Governed Structured Content for CMC
How Regulators Evaluate Change, Why Variations Break, and Where Organizations Stall Without Structural Control How governed structured content restores control
Docuvera for Chemistry Manufacturing and Controls
Download this data sheet to learn how Docuvera enables efficient authoring and updates to CMC documentation throughout every step of the pharmaceutical manufacturing process.